ASX Announcements - Actinogen

Array ( [2020] => Array ( [February] => Array ( [0] => 2615 [1] => 2612 ) [January] => Array ( [0] => 2610 [1] => 2608 [2] => 2606 [3] => 2604 [4] => 2597 ) ) [2019] => Array ( [December] => Array ( [0] => 2595 [1] => 2589 ) [November] => Array ( [0] => 2574 [1] => 2570 [2] => 2564 [3] => 2562 [4] => 2554 ) [October] => Array ( [0] => 2527 [1] => 2522 [2] => 2514 [3] => 2511 [4] => 2487 ) [September] => Array ( [0] => 2482 [1] => 2479 [2] => 2477 ) [August] => Array ( [0] => 2471 [1] => 2469 ) [July] => Array ( [0] => 2454 [1] => 2448 ) [June] => Array ( [0] => 2444 [1] => 2439 ) [May] => Array ( [0] => 2437 [1] => 2413 [2] => 2435 [3] => 2409 [4] => 2405 [5] => 2402 ) [April] => Array ( [0] => 2353 [1] => 2351 [2] => 2314 [3] => 2310 [4] => 2308 [5] => 2305 [6] => 2296 [7] => 2294 [8] => 2291 [9] => 2287 ) [March] => Array ( [0] => 2281 [1] => 2279 [2] => 2277 [3] => 2271 [4] => 2266 [5] => 2258 [6] => 2254 ) [February] => Array ( [0] => 2251 [1] => 2238 [2] => 2234 [3] => 2231 ) [January] => Array ( [0] => 2228 [1] => 2214 ) ) [2018] => Array ( [December] => Array ( [0] => 2169 [1] => 2167 [2] => 2165 [3] => 2163 ) [November] => Array ( [0] => 2136 [1] => 2134 [2] => 2116 [3] => 2114 [4] => 2112 [5] => 2110 [6] => 2108 [7] => 2102 [8] => 2100 [9] => 2076 [10] => 2074 [11] => 2071 ) [October] => Array ( [0] => 2056 [1] => 2054 [2] => 2050 [3] => 2052 [4] => 2047 [5] => 2043 [6] => 2041 [7] => 2039 [8] => 2030 [9] => 2028 [10] => 2025 ) [September] => Array ( [0] => 2015 [1] => 2009 [2] => 2007 [3] => 1996 ) [August] => Array ( [0] => 1987 [1] => 1985 [2] => 1962 [3] => 1957 ) [July] => Array ( [0] => 1918 [1] => 1910 [2] => 1905 [3] => 1903 [4] => 1901 [5] => 1891 [6] => 1889 [7] => 1887 [8] => 1884 [9] => 1882 [10] => 1877 [11] => 1875 [12] => 1870 [13] => 1868 [14] => 1866 [15] => 1864 ) [June] => Array ( [0] => 1852 [1] => 1838 [2] => 1834 [3] => 1831 ) [May] => Array ( [0] => 1823 [1] => 1812 [2] => 1810 [3] => 1807 [4] => 1796 [5] => 1794 [6] => 1792 [7] => 1790 [8] => 1771 [9] => 1769 [10] => 1767 [11] => 1752 [12] => 1750 [13] => 1742 ) [April] => Array ( [0] => 1720 [1] => 1716 [2] => 1714 [3] => 1706 [4] => 1690 ) [March] => Array ( [0] => 1677 [1] => 1697 [2] => 1648 ) [February] => Array ( [0] => 1625 [1] => 1615 [2] => 1607 ) [January] => Array ( [0] => 1598 [1] => 1590 [2] => 1583 [3] => 1581 [4] => 1579 [5] => 1577 [6] => 1567 ) ) [2017] => Array ( [December] => Array ( [0] => 1564 [1] => 1562 [2] => 1559 [3] => 1552 [4] => 1549 [5] => 1542 [6] => 1540 [7] => 1537 [8] => 1523 [9] => 1521 [10] => 1519 [11] => 1508 [12] => 1506 [13] => 1504 ) [November] => Array ( [0] => 1502 [1] => 1500 [2] => 1498 [3] => 1496 [4] => 1494 [5] => 1491 [6] => 1488 [7] => 1484 [8] => 1466 ) [October] => Array ( [0] => 1460 [1] => 1445 [2] => 1443 [3] => 1441 [4] => 1438 [5] => 1414 [6] => 1407 ) [September] => Array ( [0] => 1377 [1] => 1353 ) [August] => Array ( [0] => 1337 [1] => 1339 [2] => 1329 [3] => 1326 [4] => 1324 ) [July] => Array ( [0] => 1290 [1] => 1286 [2] => 1282 [3] => 1259 [4] => 1235 ) [June] => Array ( [0] => 1094 [1] => 957 [2] => 317 ) [May] => Array ( [0] => 220 [1] => 225 [2] => 224 ) [April] => Array ( [0] => 226 [1] => 228 [2] => 323 [3] => 325 ) [March] => Array ( [0] => 327 [1] => 329 [2] => 332 [3] => 334 [4] => 336 [5] => 338 [6] => 340 [7] => 342 ) [February] => Array ( [0] => 344 [1] => 346 [2] => 348 [3] => 350 ) [January] => Array ( [0] => 352 [1] => 354 [2] => 356 [3] => 358 ) ) [2016] => Array ( [December] => Array ( [0] => 372 [1] => 374 ) [November] => Array ( [0] => 377 [1] => 379 [2] => 381 [3] => 383 [4] => 385 ) [October] => Array ( [0] => 387 [1] => 391 [2] => 389 [3] => 393 [4] => 395 [5] => 397 ) [September] => Array ( [0] => 399 [1] => 401 [2] => 403 ) [August] => Array ( [0] => 405 [1] => 407 [2] => 409 [3] => 411 ) [July] => Array ( [0] => 427 [1] => 433 [2] => 434 [3] => 435 [4] => 436 ) [June] => Array ( [0] => 437 [1] => 440 ) [May] => Array ( [0] => 441 [1] => 446 [2] => 448 [3] => 449 ) [April] => Array ( [0] => 600 ) [March] => Array ( [0] => 454 [1] => 455 ) [February] => Array ( [0] => 456 [1] => 460 ) [January] => Array ( [0] => 1295 [1] => 461 ) ) [2015] => Array ( [December] => Array ( [0] => 462 ) [November] => Array ( [0] => 470 [1] => 468 [2] => 469 [3] => 471 [4] => 472 ) [October] => Array ( [0] => 473 [1] => 478 [2] => 479 [3] => 480 ) [September] => Array ( [0] => 481 [1] => 486 [2] => 487 ) [August] => Array ( [0] => 489 [1] => 488 [2] => 490 [3] => 491 [4] => 492 [5] => 493 [6] => 494 ) [July] => Array ( [0] => 495 [1] => 498 ) [June] => Array ( [0] => 499 [1] => 500 ) [May] => Array ( [0] => 501 [1] => 509 [2] => 510 [3] => 511 [4] => 512 [5] => 513 [6] => 514 [7] => 515 [8] => 524 [9] => 525 [10] => 526 [11] => 527 [12] => 528 [13] => 529 [14] => 530 ) [April] => Array ( [0] => 531 [1] => 538 [2] => 539 [3] => 540 [4] => 541 [5] => 542 [6] => 543 [7] => 545 [8] => 548 [9] => 550 [10] => 551 [11] => 555 [12] => 556 ) [March] => Array ( [0] => 557 [1] => 562 [2] => 563 [3] => 564 ) [February] => Array ( [0] => 565 [1] => 567 [2] => 573 [3] => 574 [4] => 575 [5] => 576 ) [January] => Array ( [0] => 577 [1] => 582 [2] => 583 [3] => 584 ) ) [2014] => Array ( [December] => Array ( [0] => 360 [1] => 362 [2] => 364 [3] => 366 [4] => 368 [5] => 370 ) ) )

February

20.02.2020	Appendix 4D & Half-Year Financial Statements
17.02.2020	Additional R&D Tax Incentive rebate received

January

31.01.2020	Appendix 3Y-Dr Bill Ketelbey
31.01.2020	ACW – ASIC Form 484
31.01.2020	Final share buy-back notice – Appendix 3F
28.01.2020	December 2019 Quarterly Update
08.01.2020	Actinogen at SACHS Forum and JP Morgan week

December

18.12.2019	Review of 2019 and outlook
13.12.2019	Share Cancellation – Employee Share Plan

November

27.11.2019	Managing Director share loan repayment
25.11.2019	Results of Annual General Meeting
25.11.2019	ACW – Managing Director’s AGM Presentation
25.11.2019	ACW 2019 AGM Chairman’s Address
20.11.2019	ACW – Response to ASX Price Query

October

24.10.2019	R&D Tax Incentive rebate received of $4.58 million
24.10.2019	September 2019 Quarterly Update
22.10.2019	Annual Report to shareholders year ended 30 June 2019
22.10.2019	ACW – Notice of Annual General Meeting/Proxy Form
01.10.2019	Cognitive improvement demonstrated with Xanamem

September

30.09.2019	Actinogen Medical Conference Call
27.09.2019	Notification of 2019 Annual General Meeting Date
27.09.2019	Trading Halt

August

16.08.2019	Appendix 4G
16.08.2019	Appendix 4E & Annual Report

July

30.07.2019	June 2019 Quarterly Update
03.07.2019	Clinical Development and Scientific Conference Update

June

26.06.2019	Xanamem Clinical Development and Investor Update
03.06.2019	Actinogen Medical participating in the BIO 2019 Convention

May

29.05.2019	XanaHES Trial to Continue
10.05.2019	Ceasing to be a substantial holder
08.05.2019	Ceasing to be a substantial holder from AEF
07.05.2019	Phase II Alzheimer’s Disease Trial – results
03.05.2019	Trading Halt
01.05.2019	Actinogen Updated Investor Presentation

April

24.04.2019	March 2019 Quarterly Update
23.04.2019	Change in substantial holding
15.04.2019	Lapse of Options
12.04.2019	Appendix 3Y-Mr Malcolm McComas
12.04.2019	Appendix 3B
10.04.2019	New Clinical Development Opportunities for Xanamem
04.04.2019	Cleansing Notice
04.04.2019	Appendix 3B
04.04.2019	Appendix 3X-Malcolm McComas
04.04.2019	Actinogen Medical appoints new Non-Executive Director

March

26.03.2019	DSMB again reaffirms XanADu trial to continue without change
22.03.2019	Change in substantial holding (Replacement Form 604)
22.03.2019	Change in substantial holding
21.03.2019	Actinogen Updated Investor Presentation
19.03.2019	Appendix 3B
14.03.2019	Becoming a substantial holder
04.03.2019	Amended-Notification of Expiry of Listed Options

February

27.02.2019	Notification of Expiry of Listed Options
22.02.2019	ACW-Appendix 4D & Half-Year Financial Statements 31 Dec 2018
11.02.2019	First participant dosed in important new Xanamem study: XanaHES
04.02.2019	Appendix 3B

January

29.01.2019	December 2018 Quarterly Update
07.01.2019	ACW Presents at SACHS Neuroscience Forum during JPM Week

December

13.12.2018	Appendix 3Y-Dr George Morstyn
13.12.2018	Appendix 3Y-Dr Bill Ketelbey
13.12.2018	Appendix 3Y-Dr Geoff Brooke
13.12.2018	Appendix 3B

November

30.11.2018	Cleansing Notice
30.11.2018	Appendix 3B-Exercise of Options
28.11.2018	Appendix 3Z-Dr Jason Loveridge
28.11.2018	Retirement of Dr Jason Loveridge as a Non-Executive Director
28.11.2018	Results of Annual General Meeting (AGM)
28.11.2018	Managing Director’s AGM Presentation
28.11.2018	Chairman’s AGM Address
26.11.2018	Final patient enrolled in landmark Alzheimer’s trial-XanADu
26.11.2018	Actinogen updated investor presentation
14.11.2018	Cleansing Notice
14.11.2018	Appendix 3B-Exercise of Options
08.11.2018	Supportive research highlights cortisol hypothesis

October

31.10.2018	September 2018 Quarterly Update
31.10.2018	Vesting Conditions Met
30.10.2018	Actinogen to be showcased at AusBiotech Invest 2018
29.10.2018	Enrolment target achieved for major Alzheimer’s trial-XanADu
24.10.2018	XanADu trial to be presented at global Alzheimer conference
23.10.2018	Annual Report to Shareholders year ended 30 June 2018
23.10.2018	Notice of Annual General Meeting/Proxy Form
22.10.2018	Recruitment to close for important Alzheimer’s trial-XanADu
17.10.2018	Actinogen to be showcased at key conferences
16.10.2018	Becoming a substantial holder from AEF
10.10.2018	R&D Tax Rebate Received Totalling $3.15 Million

September

28.09.2018	Notification of 2018 Annual General Meeting Date
18.09.2018	Cleansing Notice
18.09.2018	Appendix 3B-Exercise of Options
11.09.2018	Actinogen to Present to Investors in Singapore & Sydney

August

29.08.2018	Appendix 4G
29.08.2018	Appendix 4E & Financial Statements
22.08.2018	DSMB reaffirms recommendation to continue XanADu without change
15.08.2018	XanADu Patient Enrolment Advancing Towards Completion

July

30.07.2018	Updated Xanamem Clinical Development Program
25.07.2018	ACW June 2018 Quarterly Report
24.07.2018	Cleansing Notice
24.07.2018	Appendix 3B
24.07.2018	Ceasing to be a substantial holder
17.07.2018	Placement under Share Purchase Plan Shortfall
16.07.2018	Appendix 3Y-Dr Bill Ketelbey
16.07.2018	Appendix 3Y-Dr Geoff Brooke
13.07.2018	Appendix 3B-Share Purchase Plan
12.07.2018	Share Purchase Plan Completed
12.07.2018	Cleansing Notice
12.07.2018	Appendix 3B
06.07.2018	New Study Sites Added to Accelerate Patient Recruitment
05.07.2018	Cleansing Notice
05.07.2018	Appendix 3B – Exercise of Options
05.07.2018	Results of Meeting

June

19.06.2018	Change of Address
06.06.2018	Share Purchase Plan
05.06.2018	Notice of General Meeting/Proxy Form
05.06.2018	Appendix 3Y-Dr George Morstyn

May

31.05.2018	Becoming a substantial holder
31.05.2018	Actinogen Medical to present at BIO International 2018
31.05.2018	Change in substantial holding
30.05.2018	Ceasing to be a substantial holder
28.05.2018	Information Required Under ASX Listing Rule 3.10.5A
28.05.2018	Cleansing Notice
28.05.2018	Appendix 3B
28.05.2018	Actinogen Medical Investor Conference Call
23.05.2018	Placement to Raise $15m with Cornerstone Investment by Leading USA Biotech Investor
23.05.2018	XanADu Interim Analysis-Continuation Without Change
21.05.2018	Trading Halt
14.05.2018	Cleansing Notice
14.05.2018	Appendix 3B-Exercise of Options
10.05.2018	XanADu Interim Analysis on track for May/June

April

26.04.2018	March 2018 Quarterly Report
18.04.2018	Cleansing Notice
18.04.2018	Appendix 3B-Exercise of Options
11.04.2018	New Analyst Report on Actinogen Medical
03.04.2018	Appendix 3B

March

21.03.2018	Mid-Way Point Reached in Landmark Alzheimer’s Trial – XanADu
19.03.2018	Investor Presentation
07.03.2018	Invitation to Investor Briefing

February

15.02.2018	Appendix 4D & Half-Year Financial Statements
12.02.2018	Strong Recruitment Progress in Alzheimer’s Trial
06.02.2018	New Data Supports Cortisol Hypothesis

January

31.01.2018	ACW – December 2017 Quarterly Report
29.01.2018	ACW – Change in substantial holding
22.01.2018	Appendix 3Y-Dr Geoff Brooke
22.01.2018	Cleansing Notice
22.01.2018	Appendix 3B
18.01.2018	Results of Meeting
02.01.2018	Lapse of Unlisted Options

December

21.12.2017	Change of Directors Interest Notice x 3
21.12.2017	Appendix 3B
18.12.2017	Notice of General Meeting/Proxy Form
14.12.2017	Completion of Cancellation of Unvested Loan Shares
13.12.2017	Change in substantial holding
08.12.2017	Cleansing Notice
08.12.2017	Appendix 3B-Placement
07.12.2017	Letter to Ineligible Shareholders
01.12.2017	Letter to Optionholders
01.12.2017	Appendix 3B
01.12.2017	Prospectus
01.12.2017	Appendix 3X – Dr Morstyn
01.12.2017	Appendix 3B
01.12.2017	Amgen Pioneer Dr George Morstyn Joins Actinogen Board

November

29.11.2017	Results of Annual General & Special General Meetings
29.11.2017	Early Efficacy & Safety Data Planned for XanADu Trial
29.11.2017	Placement Fully Funds Completion of XanADu Alzheimer’s Trial
29.11.2017	Managing Director’s Annual General Meeting Presentation
29.11.2017	Chairman’s Annual General Meeting Address
27.11.2017	Trading Halt Request
22.11.2017	Leading Alzheimer’s Researchers to Address Shareholders
15.11.2017	R&D Rebate Received Totalling $1.22 Million
02.11.2017	Amgen Pioneer to Join Actinogen Board

October

30.10.2017	Quarterly Update & Appendix 4C
23.10.2017	Annual Report to Shareholders
23.10.2017	Notice of Special General Meeting & Proxy Form
23.10.2017	Notice of Annual General Meeting/Proxy Form
17.10.2017	Actinogen to be showcased at key conferences
12.10.2017	Investor Newsletter
11.10.2017	Final Major Market Patent Granted for Xanamem

September

22.09.2017	Lapse of Unlisted Options
07.09.2017	First patient completes landmark Alzheimer’s disease trial

August

18.08.2017	Appendix 4E & Financial Statements
18.08.2017	Appendix 4G
16.08.2017	First UK patient treated in ground-breaking Alzheimer’s clinical trial
14.08.2017	Final Director’s Interest Notice
14.08.2017	Resignation of Director

July

26.07.2017	June Quarterly Update
19.07.2017	Actinogen Presenting at Bioshares Biotech 2017 Summit
12.07.2017	Appendix 3B – Issue of Employee Options
07.07.2017	Appendix 3Y – Change of Director’s Interest Notice
03.07.2017	Lapse of Unlisted Options

June

22.06.2017	First US patients treated in landmark Alzheimer’s disease trial
19.06.2017	Actinogen Medical attending BIO 2017
01.06.2017	First UK site goes live in global Alzheimer’s disease Clinical Trial

May

16.05.2017	First patient treated in landmark Alzheimer’s disease clinical trial
09.05.2017	Appendix 3B – Exercise of Options
09.05.2017	Section 708A Notice

April

26.04.2017	Becoming a substantial holder
26.04.2017	Section 708A Notice
26.04.2017	Appendix 3B – Exercise of Options
26.04.2017	March Quarterly Update

March

29.03.2017	Appendix 3Y – Change of Director’s Interest Notice
27.03.2017	Latest Investor Presentation
27.03.2017	Appendix 3Y – Change of Director’s Interest Notice
27.03.2017	Appendix 3B
16.03.2017	Quarterly Investor Newsletter
08.03.2017	TGA Regulatory Approval for Alzheimer’s Phase II Trial
01.03.2017	Appendix 3X – Initial Director’s Interest Notice
01.03.2017	Actinogen Medical Appoints Dr Geoff Brooke as Chairman

February

27.02.2017	Actinogen Medical Financial Results
10.02.2017	UK Regulatory Approval for Alzheimer’s Disease Clinical Trial – XanADu
09.02.2017	Xanamem research published in prestigious medical journal
06.02.2017	Issue of Employee & Advisor Options

January

23.01.2017	Appendix 4C – Quarterly
09.01.2017	Ceasing to be a substantial holder
03.01.2017	Lapse of Unlisted Options
03.01.2017	FDA Approval to Commence Alzheimer’s Disease Clinical Trial

December

19.12.2016	Significant Advance in Development of Alzheimer’s Drug
06.12.2016	Xanamem Research Presented at CTAD

November

30.11.2016	Results of Annual General Meeting
30.11.2016	Retirement of Martin Rogers as Chairman of Actinogen Medical
30.11.2016	Appendix 3Z
30.11.2016	Chairman’s AGM Address
30.11.2016	CEO’s Presentation to AGM

October

26.10.2016	Appendix 4C – Quarterly
24.10.2016	Annual Report to Shareholders
24.10.2016	Notice of Annual General Meeting / Proxy Form
14.10.2016	Ceasing to be a Substantial Holder
06.10.2016	Ceasing to be a Substantial Holder
05.10.2016	Changes to the Actinogen Medical Board

September

29.09.2016	FDA Feedback on Xanamem Alzheimer’s Trial
05.09.2016	R&D Tax Rebate
01.09.2016	Investor Update – August 2016

August

31.08.2016	Appendix 4G
31.08.2016	Appendix 4E & Financial Statements
24.08.2016	Ceasing to be a Substantial Shareholder
17.08.2016	Less Than Marketable Parcel Sale

July

28.07.2016	Landmark Research on Excess Cortisol & Alzheimer’s Disease
20.07.2016	US Patent Granted – Further Extends Xanamem Protection
15.07.2016	US Roadshow Investor Presentation
15.07.2016	Appendix 4C Quarterly
08.07.2016	Issue of Employee Options

June

29.06.2016	Xanamem and AIBL Data Showcase Cortisol Hypothesis in Alzheimer’s Disease
08.06.2016	US FDA Feedback Enhances Alzheimer’s Study

May

20.05.2016	Change of Share Register Notification
06.05.2016	Section 708A Notice
06.05.2016	Appendix 3B
03.05.2016	BioEquity & AusBiotech Asia Investor Presentation May 2016

April

15.04.2016

Appendix 4C – Quarterly

March

22.03.2016	Launch of XanADu Phase II Clinical Trial
10.03.2016	Xanamem Cortisol Hypothesis Investor Presentation

February

19.02.2016	Appendix 4D & Half Year Report
09.02.2016	R&D Tax Rebate

January

27.01.2016	Appendix 4C – Quarterly
04.01.2016	Appendix 3Y – Dr Bill Ketelbey

December

01.12.2015

Investor Update – December 2015

November

17.11.2015	Change of Company Name
12.11.2015	Results of AGM
12.11.2015	CEO’s AGM Presentation
12.11.2015	Chairman’s AGM Address
06.11.2015	Release of Securities from Voluntary Escrow

October

15.10.2015	Appendix 4C – Quarterly
07.10.2015	Understanding Alzheimer’s Symposium
07.10.2015	Annual Report to Shareholders
07.10.2015	Notice of Annual General Meeting and Proxy Form

September

30.09.2015	Expiry of Listed Options
29.09.2015	Positive Trial Results for Alzheimer’s Drug Xanamem
28.09.2015	Trading Halt

August

31.08.2015	Appendix 4G
31.08.2015	Expiry of Listed Options & Waiver of Listing Rule 6.24
31.08.2015	Appendix 4E & Financial Statements
17.08.2015	Investor Update August 2015
12.08.2015	Employee Share Plan Vesting Conditions Met
11.08.2015	Employee Share Plan Vesting Conditions Met
11.08.2015	Clinical Trial Successfully Completed with Xanamem

July

16.07.2015	Appendix 4C – Quarterly
07.07.2015	Investor Roadshow Presentation

June

26.06.2015	Change of Address & Executive Chairman Agreement
11.06.2015	Excellent Research Progress with Promising Alzheimer’s Drug

May

21.05.2015	Employee Share Plan Vesting Conditions Met
21.05.2015	ASX Spotlight Series Singapore/Hong Kong May 2015
20.05.2015	Appendix 3B
20.05.2015	Appendix 3Y: Dr Anton Uvarov
20.05.2015	Appendix 3Y: Dr Bill Ketelbey
20.05.2015	Appendix 3Y: Dr Jason Loveridge
20.05.2015	Appendix 3Y: Martin Rogers
14.05.2015	Notice of Change of Interests of Substantial Holder
12.05.2015	Successful Completion of First Stage of Alzheimer’s Drug Trial
07.05.2015	Change in Substantial Holding
07.05.2015	Ceasing to be a Substantial Holder
06.05.2015	Information Required Under Listing Rule 3.10.5A
06.05.2015	Section 708A Notice
06.05.2015	Appendix 3B
01.05.2015	Notice Under ASIC Class Order (CO 09-425)

April

30.04.2015	Share Purchase Plan
28.04.2015	Change in Substantial Shareholding
27.04.2015	Change in Substantial Shareholding x 2
24.04.2015	Ethics Approval Granted for Second Stage of Phase I Study
24.04.2015	Successful Capital Raising to Support Alzheimer’s Research
24.04.2015	Appendix 4C: Quarterly
22.04.2015	Trading Halt
16.04.2015	Further Clinical Trial Update on Xanamem
16.04.2015	Xanamem Clinical Advisory Board (XCAB) Conference Call Transcript
15.04.2015	Investor Update – April 2015
13.04.2015	EU Patent Granted – Further Extends Xanamem Protection
13.04.2015	Investor Presentation – April 2015
13.04.2015	Xanamem Clinical Advisory Board (XCAB) Conference Call

March

24.03.2015	Clinical Trial Update – Xanamem Drug for Alzheimer’s Dementia
17.03.2015	Powerhouse Alzheimer’s Advisory Board to Drive Xanamem Development
12.03.2015	Response to Price Query Letter
09.03.2015	Investor Presentation – March 2015

February

27.02.2015	Appendix 4D & Half Year Report
24.02.2015	First Participants Recruited for Second Phase I Xanamem Study
24.02.2015	Employee Share Plan Vesting Conditions Met
17.02.2015	Investor Presentation – February 2015
16.02.2015	Ethics Approval Granted for Second Phase I Study of Xanamem
16.02.2015	Investor Update – February 2015

January

29.01.2015	Appendix 4C: Quarterly
16.01.2015	Employee Share Plan Vesting Conditions Met
09.01.2015	US Investor Presentation – January 2015
07.01.2015	Response to ASX Query – Price Query

December

18.12.2014	ACW Board Changes
18.12.2014	Appendix 3Z – Final Director’s Interest Notice
18.12.2014	Appendix 3X – Dr Bill Ketelbey
15.12.2014	Section 708A Notice
15.12.2014	Appendix 3B
15.12.2014	ACW Appoints Dr Bill Ketelbey as CEO